Intermediate Monocyte Subsets for Cardiovascular Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cardiovascular disease (CVD) and subclinical CVD lack effectiveness in identifying immune aspects and early detection, relying heavily on expensive scans and insufficient biomarkers that do not fully assess inflammatory risk.
Innovation Solution
A method involving the isolation of immune cells from a subject's sample to detect specific subsets of intermediate monocyte cell populations (INT1, INT2, INT3, INT4) using surface marker gating, comparing their proportions to a statistical sample, and determining increased risk based on decreases in INT2 and INT3 and increases in INT4 subsets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional CVD detection methods are used, then detection can be performed with existing tools, but detection precision and immune aspect identification are insufficient
Solution Approach 1:
The patent segments the intermediate monocyte population into four distinct subsets (INT1, INT2, INT3, INT4) based on specific surface marker expressions (CD137, CD154, CD163, CCR2, CCR4, CCR5). This segmentation allows for precise identification of different immune cell populations with specific functional roles in cardiovascular disease, thereby improving detection precision without requiring overly complex equipment.
Solution Approach 2:
The patent applies local quality by using specific surface marker profiles to identify and differentiate individual cell subsets within the intermediate monocyte population. Each subset (INT1-INT4) is characterized by a unique combination of marker expressions, allowing for targeted detection of specific immune responses associated with CVD risk while maintaining a manageable analytical framework.
2Loss of information
If immune cell subsets are analyzed in detail, then immune aspect detection is improved, but analysis complexity and time increase
Solution Approach 1:
The patent employs preliminary action by using flow cytometry with pre-defined gating strategies and surface marker panels to simultaneously identify and quantify all four intermediate monocyte subsets in a single assay. This approach captures comprehensive immune information about CVD risk from blood samples without requiring sequential, time-consuming analysis steps for each cell subset.
Solution Approach 2:
The patent achieves universality by developing a multi-functional flow cytometry assay that can detect multiple immune cell subsets (INT1-INT4) with different surface marker profiles using a single analytical platform. This multi-functional approach allows simultaneous assessment of various immune aspects of CVD risk without requiring separate specialized assays for each cell type, thereby reducing overall analysis time.
Data Source
AI summary
The present invention includes methods to determine a risk of a cardiovascular disease (CVD) or a subclinical CVD (sCVD) in a subject, by detecting a subset of intermediate monocyte cell populations in the immune cells, wherein a percentage of the subsets as compared to a total intermediate monocyte cell population present in the isolated immune cells is determined; comparing a proportion of the subsets subset of intermediate monocyte cell populations determined with a statistical sample representative of a proportion of equivalent subsets in a total intermediate monocyte cell populations from a subject that does not have a cardiovascular disease; and determining that the subject has an increased risk for cardiovascular disease where the subject has a decrease in the certain subsets, has an increase in another subset, or both, as compared to the statistical sample.